key: cord-0772039-1fp5yrx7
authors: Kratzer, Bernhard; Trapin, Doris; Ettel, Paul; Körmöczi, Ulrike; Rottal, Arno; Tuppy, Friedrich; Feichter, Melanie; Gattinger, Pia; Borochova, Kristina; Dorofeeva, Yulia; Tulaeva, Inna; Weber, Milena; Grabmeier‐Pfistershammer, Katharina; Tauber, Peter A.; Gerdov, Marika; Mühl, Bernhard; Perkmann, Thomas; Fae, Ingrid; Wenda, Sabine; Führer, Harald; Henning, Rainer; Valenta, Rudolf; Pickl, Winfried F.
title: Immunological imprint of COVID‐19 on human peripheral blood leukocyte populations
date: 2020-11-22
journal: Allergy
DOI: 10.1111/all.14647
sha: cd2caafa07c5597fcba302f7686d8511f46281ae
doc_id: 772039
cord_uid: 1fp5yrx7

BACKGROUND: SARS‐CoV‐2 has triggered a pandemic that is now claiming many lives. Several studies have investigated cellular immune responses in COVID‐19‐infected patients during disease but little is known regarding a possible protracted impact of COVID‐19 on the adaptive and innate immune system in COVID‐19 convalescent patients. METHODS: We used multiparametric flow cytometry to analyze whole peripheral blood samples and determined SARS‐CoV‐2‐specific antibody levels against the S‐protein, its RBD‐subunit, and viral nucleocapsid in a cohort of COVID‐19 convalescent patients who had mild disease ~10 weeks after infection (n = 109) and healthy control subjects (n = 98). Furthermore, we correlated immunological changes with clinical and demographic parameters. RESULTS: Even ten weeks after disease COVID‐19 convalescent patients had fewer neutrophils, while their cytotoxic CD8(+) T cells were activated, reflected as higher HLA‐DR and CD38 expression. Multiparametric regression analyses showed that in COVID‐19‐infected patients both CD3(+)CD4(+) and CD3(+)CD8(+) effector memory cells were higher, while CD25(+)Foxp3(+) T regulatory cells were lower. In addition, both transitional B cell and plasmablast levels were significantly elevated in COVID‐19‐infected patients. Fever (duration, level) correlated with numbers of central memory CD4(+) T cells and anti‐S and anti‐RBD, but not anti‐NC antibody levels. Moreover, a “young immunological age” as determined by numbers of CD3(+)CD45RA(+)CD62L(+)CD31(+) recent thymic emigrants was associated with a loss of sense of taste and/or smell. CONCLUSION: Acute SARS‐CoV‐2 infection leaves protracted beneficial (ie, activation of T cells) and potentially harmful (ie, reduction of neutrophils) imprints in the cellular immune system in addition to induction of specific antibody responses.

Current data indicate a long and relatively mild initial course of the disease after SARS-CoV-2 infection, which may be followed by a severe course after a median time of 8 days from the first symptoms.

The mild period may be followed by a period of breathlessness (approximately on day 8), which may turn into acute respiratory distress syndrome (ARDS) on day 9, followed by admission to intensive care on day 10.5. [15] [16] [17] Acute infection with SARS-CoV-2 can be proven by detecting nucleic acids from the virus in nasopharyngeal swabs or lavages. 18 After the acute infection, SARS-CoV-2-specific antibodies 9, 16 are usually formed, which coincides with the clearance of the virus from the body and a delayed response might be associated with mortality. 19 However, SARS-CoV-2-specific antibodies have varying specificities and titers for different antigens/epitopes and it has been shown that antibodies from convalescents after a mild COVID-19 infection cannot always prevent the virus from binding to ACE2 and may therefore not have a protective effect. 9 Similarly, several studies have investigated the effect(s) of a primary SARS-CoV-2 infection on leukocyte populations in the body in general, and on T and B lymphocyte subsets in particular. Also, the SARS-CoV-2-specific T cell response has been investigated by several research groups. 17, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Notably, memory CD4 + T cells have been suggested to mediate protective immunity against the previously circulating CoV-strains SARS-CoV 30 and MERS, 31 respectively, and CD8 + memory T cell responses have been observed in SARS-CoV convalescent patients years after primary infection. 32 However, regarding infection with the novel coronavirus SARS-CoV-2 recent reports have revealed conflicting results with one study (analyzing PB lymphocyte subsets in 44 patients) pointing toward reduced T memory and T regulatory cell populations in severe COVID-19-infected patients, suggesting that immune dysregulation potentially leads to aggravated inflammatory responses in patients. 28 In contrast, another study provided evidence for segregation between memory T cells from patients with acute severe or acute moderate COVID-19 disease and the development of memory T cells from recently convalescent individuals (42-58 days after infection) and healthy controls. 33 The latter study found only very moderate changes in a group of 40 COVID-19 convalescent patients who underwent a mild COVID-19 disease course (49-64 days after disease onset).

However, the available studies on cellular immune responses were mainly conducted in patients suffering from acute COVID-19 but little is known about the protracted effects of COVID-19 on cellular immune responses. Consequently, there is a need for systematic studies analyzing COVID-19 effects on cellular immune responses in cohorts of well documented COVID-19 convalescent patients, in particular, for those who had experienced mild disease constituting the majority of cases, to understand if and how the infection continues to stimulate and/or perturb the immune system of the convalescent host. It is also unclear how possible changes in peripheral leukocyte/lymphocyte compartments correlate with SARS-CoV-2-specific antibody levels and/or clinical symptoms.

Accordingly, the aims of this study were to identify the immunological imprint of primary COVID-19 infection on peripheral blood (PB) cell populations and antibody levels. We were especially interested whether distinct changes in blood cell or antibody parameters would separate COVID-19 convalescent patients from healthy subjects and whether we could define parameters which may be associated with the disease course, disease duration, pre-existing medical conditions, regular medications, or demographic parameters. Thus, we performed here a systematic study to investigate the distribution of leukocyte subsets in peripheral blood with a special interest in T and B lymphocyte subpopulations of COVID-19 convalescent patients 10 weeks after mild SARS-CoV-2 infection and compared results with a large, age-matched, healthy control group, which was recruited in parallel and was negative for SARS-CoV-2 antibodies and had a negative SARS-CoV-2 rtPCR at the time of venipuncture. Therefore, and in order to unequivocally determine leukocyte, T and B lymphocyte populations we performed whole-blood multiparametric flow cytometry on COVID-19-infected patient and control peripheral blood (PB) samples. Furthermore, we determined SARS-CoV-2-specific antibody levels against S protein, its subunit the RBD protein, and the viral nucleocapsid protein and analyzed whether thymic and/or bone marrow output were affected in COVID-19-infected patients who underwent a mild disease course.

Between May 11, 2020, and July 2, 2020, 109 patients diagnosed with COVID-19 disease 10 weeks previously (71.2 ± 16.5 days) were enrolled into this study. The 109 patients had rtPCR-confirmed (n = 92, 84.4%) and/or SARS-CoV-2 antibody-confirmed (Elecsys ® Anti-SARS-CoV-2 assay Roche) (n = 108 tested, n = 107 positive, 99.1%) COVID-19 disease. 34 In parallel, 98 healthy control subjects, who were reportedly asymptomatic for the last 10 weeks and who were SARS-CoV-2 negative by certified SARS-CoV-2 antibody test (Elecsys ® Anti-SARS-CoV-2 assay Roche) and had a negative rtPCR test for SARS-CoV-2 at the time of venipuncture, were enrolled into the study. Similar to the COVID-19-infected patients also the HC collective had different co-morbidities as specified in Table 1 . All patients gave their written informed consent in accordance with the Declaration of Helsinki.

The study was approved by the Ethics Committee of the Medical University of Vienna (EK No.: 1302/2020). Venous blood was drawn from all subjects and was either EDTA-anticoagulated (for flow cytometric analyses and determination of lymphocyte emigration rates from thymus using TREC and bone marrow using KREC technology), heparin-anticoagulated (for cryopreservation of PBMC), or silicon dioxide coagulated (to obtain serum for determining specific antibodies).

Immunophenotyping was performed by using optimal concentrations of directly conjugated monoclonal antibodies (Table S1) Additional methods can be found in the Appendix 1 in the online repository to this article.

Between May 11, 2020, and July 2, 2020, 109 COVID-19 convalescent patients and 98 healthy control subjects were enrolled into this retrospective study. The group of COVID-19 convalescent patients and the group of healthy control subjects were well balanced regarding gender, age, height, and weight ( 

First, we determined overall peripheral blood (PB) leukocyte subpopulations in the COVID-19-infected patient collective and in healthy control subjects. Remarkably, the COVID-19 convalescent patients showed significantly less leukocytes compared with the healthy control subjects (6384 ± 1677 × 10 6 /L vs 7006 ± 1961 × 10 6 /L; P = .0156), which was due to highly significantly lower neutrophil counts (4111 ± 1477 × 10 6 /L vs 4693 ± 1588 × 10 6 /L; P = .0033) (Figure 1 ; Figure S1 and Table S3 ). Neutropenia is frequently associated with Days of hospitalization 5.9 ± 5.8 March-May, that is, when the first wave of the COVID-19 pandemic was at its peak in Austria, no capacity for additional PCR tests was available, which represents a limitation of this study.

In contrast to neutrophils, numbers of monocytes, CD3 + T cells, irrespective whether TCR alpha/beta + or TCR gamma/delta + , similar to the CD3 + CD4 + and CD3 + CD8 + T-cell subsets, CD56 + NK cells and CD19 + B cells did not reveal significant differences between COVID-19 convalescent patients and healthy control individuals ( Figure 1 and Table S3 ). However, CD3 + T cells of COVID-19 convalescent patients showed distinct signs of activation, with significantly more CD3 + T cells expressing HLA-DR on their surface (107 ± 85 × 10 6 /L vs 81 ± 54 × 10 6 /L, P = .0248; 5.78 ± 3.84% vs 4.34 ± 2.50%; P = .0054) (Table S3 ). That HLA-DR is a well-known activation antigen of human T lymphocytes 37 which is also associated with acute viral infections 38, 39 has been described previously. T-cell subset analyses revealed that the subset of cytotoxic CD3 + CD8 + T cells exclusively accounted for that difference (61 ± 65 × 10 6 /L vs 38 ± 34 × 10 6 /L; P = .0079;

3.21 ± 2.91% vs 2.05 ± 1.61%; P = .0014), while CD3 + CD4 + T cells had no increased signs of activation when compared for HLA-DR expression to those of healthy controls (33 ± 18 × 10 6 /L vs 31 ± 19 × 10 6 /L; P = .3630) ( Figure 1 and Figure S2 ). Activation of the T-cell compartment in COVID-19 convalescent patients was also evident when we examined CD38 co-expression on CD3 + T cells (4.6 ± 3.6 × 10 6 /L vs 3.5 ± 2.7 × 10 6 /L; P = .0275; 0.27 ± 0.24% vs 0.19 ± 0.14%, P = .0051), which is another important activation antigen and also an endothelial adhesion molecule known for its upregulation on virus-specific T cells. 38, 39 Notably, and in clear contrast to HLA-DR expression which was restricted to CD3 + CD8 + T cells, significant upregulation of CD38 on lymphocytes of COVID-19 convalescent patients was observed on both, CD4 + and CD8 + T cells (Table S3 ).

Notably, a dramatic increase of the subset of CD3 + CD4 + T cells coexpressing the high affinity IL-7 receptor alpha chain (CD127) irrespective of the presence (137 ± 114 × 10 6 /L vs 79 ± 106 × 10 6 /L, Table S4 ). This dramatic expansion appeared to be at the expense of Foxp3 + CD25 + CD127 -CD3 + CD4 + T regulatory cells, which were significantly reduced in patients compared with healthy controls (11 ± 15 × 10 6 /L vs 15 ± 11 × 10 6 /L, P = .0004; 27.73 ± 25.70% vs 42.10 ± 27.26%, P = .0001) (Table S4) .

Apart from the clear-cut expansion of naïve and effector CD4 + T helper cells, significantly more CD3 + CD8 + CD45RO + CD45RAmemory T cells were present in the blood of COVID-19 convalescent patients as compared to healthy controls (113 ± 79 × 10 6 /L vs 87 ± 54 × 10 6 /L; P = .0263) (Figure 2 , Figure S4B ), which was also reflected by their significantly higher relative levels among CD3 + T cells (8.58 ± 4.67% vs 6.82 ± 3.88%; P < .0045) ( Table S4 ). The elevated levels of memory T cells almost exclusively belonged to the CD45RO + CCR7effector memory subset (128 ± 89 × 10 6 /L vs 99 ± 55 × 10 6 /L; P = .0502), which was significantly higher among CD3 + CD8 + T cells ( 

Next, we determined B-cell subset distribution and found that major Table S5 ). This finding was interesting,

given the observed and above-described gross distortions of T memory cell populations in COVID-19 convalescent patients. However, CD19 + CD38 high IgM + transitional B cells were significantly higher in COVID-19 convalescent patients when compared to healthy control subjects (5.00 ± 3.07% vs 3.57 ± 2.30%; P = .0020) (Figure 3 ;

Figures S6, S7 and Table S5 ). Similarly, CD19 + CD38 + IgMplasmablasts were both absolutely (2.5 ± 1.8 × 10 6 /L vs 1.6 ± 1.3 × 10 6 /L; P = .0015) and relatively (1.56 ± 0.97% vs 1.04 ± 0.95%; P < .0001

higher in COVID-19-infected patients as compared to healthy control subjects (Figure 3; Figures S6, S7 and Table S5 ). That the current bone marrow output of B-cell precursors was not depressed in COVID-19 convalescent patients could be demonstrated by determining kappa recombination excision circles (KRECs), which were not different from the healthy control population (Figure 3 ).

In a next step, multivariate logistic regression analyses were performed 58.1%-74.3%; P < .001) and of cytotoxic CD3 + CD8 + CD45RO + CCR7effector memory T cells (AUC 60.1%; 95% CI 51.8% to 68.5%; P = .022) were clearly higher in COVID-19 convalescent individuals than HC. In contrast, relative numbers of CD3 + CD4 + CD45RA + Foxp3 + CD25 + CD127 -T regulatory cells (P = .047) and of antigenexperienced(AE)3 cytotoxic CD3 + CD8 + CD27 + CD28 -CD45RA +/-T 

Next, we performed univariate analyses in order to investigate whether blood cell parameters and/or SARS-CoV-2-specific antibody levels (S-, RBD-, and NC-protein) would correlate with clinical symptoms ( Figure 4A ), co-morbidities, and premedications of COVID-19-infected patients. Most notably, we found that convalescent patients who had more severe fever during their disease had significantly higher relative numbers of CD3 + CD4 + CD45RO + CCR7 + central memory helper T cells ( Figure 4B ) in their blood (P = .0003). In addition, relative numbers of CD3 + CD4 + CD45RO + CCR7 + central memory helper T cells were significantly associated with chills (P = .0030; data not shown), and with the number of fever days (P = .0045; Figure 4C ). These findings were corroborated by significant inverse correlations observed between highest fever and relative and absolute numbers of naïve CD3 + CD4 + CD45RO -CCR7 + T cells (P = .0025 and P = .0034, respectively; not shown).

Notably, patients who had fever during their disease also presented with significantly more activated CD19 + CD21 low CD38 low B cells 41 ( Figure 4D ; P = .0045).

Moreover, the number of fever days and the presence of fever in general (not shown), correlated well with both the levels of anti-S-protein IgG (P = .0002) and anti-RBD IgG (P = .0166) as determined by ELISA ( Figure 4E , F). In contrast, anti-NC antibodies only moderately correlated with fever/highest temperature (not shown)

but not duration of fever ( Figure 4G ).

Another very interesting finding was the fact that patients suffering from loss of taste/smell had significantly more CD3 + CD45RA + CD62L + CD31 + RTEs in their blood (P = 0.0172) ( Figure 4H ). While CD3 + CD45RA + CD62L + CD31 + recent thymic emigrant cells positively correlate with TREC numbers (P < .0001) and

negatively with biological age (P < .0001), this association was only evident when the age was determined "immunologically," that is, by multicolor flow cytometry but not upon determination of birth age.

This finding may indicate that individuals with a "young(er) immune system" are more likely to suffer from loss of taste/smell when infected by SARS-CoV-2. That loss of taste/smell represents indeed a separate clinical factor in COVID-19-infected patients, which is clearly different from, for example, the fever/coughing/fatigue-or the arthralgia/myalgia-factor was confirmed by principal component analysis (PCA), reducing clinical symptoms to factors best explaining the variance of variables, followed by rotated component matrix relation determination (Varimax-Rotation) using the collected clinical symptom categories (Table 2) . These analyses revealed seven factors defined by certain symptoms (factor 1: fever, chills, rigor, fatigue, cough; factor 2: running nose, nasal congestion, sore throat, sneeze; factor 3: arthralgia, myalgia; factor 4: conjunctivitis, other GI problems; factor 5: pneumonia, shortness of breath, wheezing; factor 6: vomiting, nausea, headache, diarrhea; convalescent patients, however, surprisingly not with disease duration and severity (fever days, fever height) although age is frequently associated with a higher mortality risk. 42 Notably, a total of 45% of COVID-19 convalescent patients took regular medications (Table S2) with 16 out of the 109 patients reporting intake of ACE-or angiotensin receptor (AT) blockers (candesartan, lisinopril, enalapril, ramipril, irbesartan, valsartan), that means, substances which have been shown to lead to increased ACE2 receptor expression in cardiac tissue in preclinical models previously. 43 While ACE/AT inhibitor intake positively correlated with the age of patients (P < .0001), it apparently did not correlate with the disease course, for example, duration of fever (P = .7316) or of clinical symptoms (P = .6131). Of significance, also 11 subjects in the control group took ACE/AT inhibitors as regular medication; thus, there was no significant difference between the patient and control group regarding ACE/AT inhibitor consumption. 53 Moreover, cytotoxic T cells are also proficient to express the canonical co-stimulatory molecules CD86 and CD80, which are essential for the priming and activation of effector T cells. 53 In addition, a previous report has shown that T cell-T-cell synapses have a major role in the generation of protective CD8 + T-cell memory since conjugated cells critically polarize each other toward the secretion of interferon-gamma (IFN-gamma). 54 We here also found increased CD38 expression on both CD4 + and CD8 + T cells of COVID-19 convalescent patients. In fact, CD38

(adenosine diphosphate (ADP) ribosyl cyclase) marks T cells with increased cytotoxic capability 38, 39 and enhanced ability to produce cytokines. 55 Furthermore, CD38 endows T cells with improved interaction with endothelial cells via CD31, 56 which has been shown to lead to improved adhesion of lymphocytes to endothelium. 57 Whether this also leads to enhanced extravasation of T cells is an open question, but it is tempting to speculate that CD38 + T cells might have an improved capability to target sites of inflammation.

Antibodies and T cells are the two main antigen-specific effector systems for resolving viral infections. Notably, both T cell subsets contribute to viral clearance. 58, 59 In fact, anti-viral CD4 + T cell responses are important for optimal antibody and CD8 + T cell responses. Thus, it is not entirely unexpected that we found significantly elevated numbers of effector memory CD4 + CD45RA + CD127 + T cells in COVID-19 convalescent patients. What is, however, surprising is the level and degree of maintenance of these cells in patients with a mild COVID-19 disease course, because we could easily identify their high numbers even without applying antigen-specific detection methods such as tetramer staining. One mechanism for the sustained expansion of these effector cells seems to be the mitigation of T regulatory responses, which is reflected by significantly lower CD25 + Foxp3 + CD127 -T cells in convalescents as compared to healthy controls ( Figure 2 and Table S4 ).

Whether the CD4 + effector cells have mere helper function for the clonal expansion of the SARS-CoV-2-specific B cells or may also exert cytotoxic cellular programs remains to be shown in future analyses. Nevertheless, besides the expanded CD4 + T cells, we also detected a significant expansion of the CD8 + effector memory pool. Moreover, two patients clearly reacted in the NC-test (36.0 and 74.1, respectively), but no anti-S-protein or anti-RBD protein antibodies were detected. Together, these findings indicate that the spectrum and magnitude of antibody specificities in COVID-19 convalescent patients may considerably vary. In this context, it will be interesting to perform a comprehensive analysis of the SARS-CoV-2-specific antibody response using a broad spectrum of virus-derived antigens and epitopes and testing of several isotypes and IgG subclasses by multiplex tests such as chips containing micro-arrayed components similar as developed for other viral infections. 64, 65 The fact that more than 25% of the convalescent patients did not mount a relevant anti-RBD antibody response fits to our earlier finding that up to 50% of convalescent patients do not mount antibodies which can inhibit the docking of the virus via RBD to its receptor, ACE2. 9 Also in this study, we found that ~50%-60% Our study thus not only reports definitive evidence for a protracted immunological imprint of COVID-19 on human peripheral leukocyte populations but also raises several new aspects of COVID-19 which require further studies.

This study was supported by grants from the "Medizinisch- Guentcheva for their help regarding recruitment and administration of study subjects. We are indebted to all individuals who participated in our study. 

A novel coronavirus outbreak of global health concern

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

A Novel Coronavirus from Patients with Pneumonia in China

A Genomic perspective on the origin and emergence of SARS-CoV-2

COVID-19: Lessons from SARS and MERS

World Health Organization. Coronavirus disease (COVID-19) outbreak

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Receptor recognition by the novel coronavirus from Wuhan: an Analysis based on decade-long structural studies of SARS coronavirus

Antibodies in serum of convalescent patients following mild COVID-19 do not always prevent virus-receptor binding

CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement

Human coronavirus 229E can use CD209L (L-SIGN) to enter cells

CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus

Identifying airborne transmission as the dominant route for the spread of COVID-19

A compendium answering 150 questions on COVID-19 and SARS-CoV-2

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan

Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2

Delayed virus-specific antibody responses associate with COVID-19 mortality

Dynamic changes in peripheral blood lymphocyte subsets in adult patients with COVID-19

Immune parameters and COVID-19 infection -associations with clinical severity and disease prognosis

Comprehensive mapping of immune perturbations associated with severe COVID-19

Reappearance of effector T cells is associated with recovery from COVID-19

Immunological and inflammatory profiles in mild and severe cases of COVID-19

Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan

Temporal changes in immune blood cell parameters in COVID-19 infection and recovery from severe infection

Changes of hematological and immunological parameters in COVID-19 patients

Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China

Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia

Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses

Overview of immune response during SARS-CoV-2 infection: Lessons from the past

Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

Neutropenia in pediatric practice

Ia determinants on stimulated human T lymphocytes. Occurrence on mitogen-and antigen-activated T cells

Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens

Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection

Phenotype and function of human T lymphocyte subsets: consensus and issues

Eight-color immunophenotyping of T-, B-, and NK-cell subpopulations for characterization of chronic immunodeficiencies

COVID-19 in a designated infectious diseases hospital outside Hubei Province, China

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Antineutrophil antibodies in infectious mononucleosis

The leukocytic response of patients with experimentally induced infectious hepatitis

Polymorphonuclear and monocyte functions in measles

Varicella infection with profound neutropenia, multisystem involvement and no sequelae

Clinical and serologic responses of volunteers infected with phlebotomus fever virus (Sicilian type)

The blood picture in rubella; its place in diagnosis

HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus

HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men

Secondary T cell-T cell synaptic interactions drive the differentiation of protective CD8+ T cells

CD38 ligation induces discrete cytokine mRNA expression in human cultured lymphocytes

Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member

Interaction between endothelium and CD4+CD45RA+ lymphocytes

Immunological memory and protective immunity: understanding their relation

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients

Effective treatment of severe COVID-19 patients with tocilizumab

Blood-borne human plasma cells in steady state are derived from mucosal immune responses

HIV microarray for the mapping and characterization of HIV-specific antibody responses

PreDicta chip-based high resolution diagnosis of rhinovirus-induced wheeze

Cross-sectional study on allergic sensitization of Austrian adolescents using molecule-based IgE profiling

Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Immunological imprint of COVID-19 on human peripheral blood leukocyte populations